Litcius/Paper detail

Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction

Kunimasa Yagi, Teruhiko Imamura, Hayato Tada, Daisuke Chujo, Jianhui Liu, Yuuki Shima, Azusa Ohbatake, Yukiko Miyamoto, Satoko Okazaki, Naoko Ito, Kaoru Nakano, Masataka Shikata, Asako Enkaku, Akiko Takikawa, Hisae Honoki, Shiho Fujisaka, Hideki Origasa, Kazuyuki Tobe

2021Journal of Diabetes Research18 citationsDOIOpen Access PDF

Abstract

Objectives. A single-arm prospective study was conducted among Japanese patients with type 2 diabetes having preserved ejection fraction. The aim was to investigate (1) whether liraglutide therapy could improve B-type natriuretic peptide (BNP) levels and diastolic cardiac function assessed by the <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mi>E</a:mi> </a:math> -wave to <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:msup> <c:mrow> <c:mi>E</c:mi> </c:mrow> <c:mrow> <c:mo>′</c:mo> </c:mrow> </c:msup> </c:math> ratio ( <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mi>E</e:mi> <e:mo>/</e:mo> <e:msup> <e:mrow> <e:mi>E</e:mi> </e:mrow> <e:mrow> <e:mo>′</e:mo> </e:mrow> </e:msup> </e:math> ) using transthoracic echocardiography (TTE), and (2) whether <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>E</g:mi> <g:mo>/</g:mo> <g:msup> <g:mrow> <g:mi>E</g:mi> </g:mrow> <g:mrow> <g:mo>′</g:mo> </g:mrow> </g:msup> </g:math> contributed to BNP improvement independent of bodyweight reduction (UMIN000005565). Methods. Patients with type 2 diabetes and <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mtext>left</i:mtext> <i:mtext> </i:mtext> <i:mtext>ventricular</i:mtext> <i:mtext> </i:mtext> <i:mtext>ejection</i:mtext> <i:mtext> </i:mtext> <i:mtext>fraction</i:mtext> <i:mtext> </i:mtext> <i:mfenced open="(" close=")"> <i:mrow> <i:mtext>LVEF</i:mtext> </i:mrow> </i:mfenced> <i:mo>≥</i:mo> <i:mn>40</i:mn> <i:mi>%</i:mi> </i:math> without heart failure symptoms were enrolled, and daily injection with liraglutide (0.9 mg) was introduced. Cardiac functions were assessed by TTE before and after 26 weeks of liraglutide treatment. Diastolic cardiac function was defined as septal <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M6"> <m:mi>E</m:mi> <m:mo>/</m:mo> <m:msup> <m:mrow> <m:mi>E</m:mi> </m:mrow> <m:mrow> <m:mo>′</m:mo> </m:mrow> </m:msup> <m:mo>≥</m:mo> <m:mn>13.0</m:mn> </m:math> . Results. Thirty-one patients were analyzed. BNP and <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M7"> <o:mi>E</o:mi> <o:mo>/</o:mo> <o:msup> <o:mrow> <o:mi>E</o:mi> </o:mrow> <o:mrow> <o:mo>′</o:mo> </o:mrow> </o:msup> </o:math> improved, with BNP levels declining from <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M8"> <q:mn>36.8</q:mn> <q:mo>±</q:mo> <q:mn>30.5</q:mn> <q:mtext> </q:mtext> <q:mtext>pg</q:mtext> <q:mo>/</q:mo> <q:mtext>mL</q:mtext> </q:math> to <s:math xmlns:s="http://www.w3.org/1998/Math/MathML" id="M9"> <s:mn>26.3</s:mn> <s:mo>±</s:mo> <s:mn>25.9</s:mn> <s:mtext> </s:mtext> <s:mtext>pg</s:mtext> <s:mo>/</s:mo> <s:mtext>mL</s:mtext> </s:math> ( <u:math xmlns:u="http://www.w3.org/1998/Math/MathML" id="M10"> <u:mi>p</u:mi> <u:mo>=</u:mo> <u:mn>0.0014</u:mn> </u:math> ) and <w:math xmlns:w="http://www.w3.org/1998/Math/MathML" id="M11"> <w:mi>E</w:mi> <w:mo>/</w:mo> <w:msup> <w:mrow> <w:mi>E</w:mi> </w:mrow> <w:mrow> <w:mo>′</w:mo> </w:mrow> </w:msup> </w:math> dropping from <y:math xmlns:y="http://www.w3.org/1998/Math/MathML" id="M12"> <y:mn>12.7</y:mn> <y:mo>±</y:mo> <y:mn>4.7</y:mn> </y:math> to <ab:math xmlns:ab="http://www.w3.org/1998/Math/MathML" id="M13"> <ab:mn>11.0</ab:mn> <ab:mo>±</ab:mo> <ab:mn>3.3</ab:mn> </ab:math> ( <cb:math xmlns:cb="http://www.w3.org/1998/Math/MathML" id="M14"> <cb:mi>p</cb:mi> <cb:mo>=</cb:mo> <cb:mn>0.0376</cb:mn> </cb:math> ). The LVEF showed no significant changes. <eb:math xmlns:eb="http://www.w3.org/1998/Math/MathML" id="M15"> <eb:mi>E</eb:mi> <eb:mo>/</eb:mo> <eb:msup> <eb:mrow> <eb:mi>E</eb:mi> </eb:mrow> <eb:mrow> <eb:mo>′</eb:mo> </eb:mrow> </eb:msup> </eb:math> improved only in patients with <gb:math xmlns:gb="http://www.w3.org/1998/Math/MathML" id="M16"> <gb:mi>E</gb:mi> <gb:mo>/</gb:mo> <gb:msup> <gb:mrow> <gb:mi>E</gb:mi> </gb:mrow> <gb:mrow> <gb:mo>′</gb:mo> </gb:mrow> </gb:msup> <gb:mo>≥</gb:mo> <gb:mn>13.0</gb:mn> </gb:math> . Favorable changes in <ib:math xmlns:ib="http://www.w3.org/1998/Math/MathML" id="M17"> <ib:mi>E</ib:mi> <ib:mo>/</ib:mo> <ib:msup> <ib:mrow> <ib:mi>E</ib:mi> </ib:mrow> <ib:mrow> <ib:mo>′</ib:mo> </ib:mrow> </ib:msup> </ib:math> were canceled when adjusted for body mass index (BMI). Multivariate linear regression analysis revealed that the left ventricular diastolic diameter and <kb:math xmlns:kb="http://www.w3.org/1998/Math/MathML" id="M18"> <kb:mo>∆</kb:mo> <kb:mi>E</kb:mi> <kb:mo>/</kb:mo> <kb:msup> <kb:mrow> <kb:mi>E</kb:mi> </kb:mrow> <kb:mrow

Topics & Concepts

Ejection fractionLiraglutideNatriuretic peptideInternal medicineCardiologyType 2 diabetesMedicineDiastolic functionReduction (mathematics)DiastoleWeight lossCardiac function curveEndocrinologyDiabetes mellitusObesityHeart failureBlood pressureMathematicsGeometryDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsDiabetes Management and Research